The US FDA has approved CSL's HEMGENIX (etranacogene dezaparvovec-drlb) as the first and only one-time gene therapy for appropriate adults with haemophilia B.
CSL secures US approval for breakthrough one-time haemophilia gene therapy
November 24, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5. Ep.36
October 19, 2026 - - Podcast -
Pharmac funding wins backing across New Zealand's political divide
October 19, 2026 - - Latest News -
Cancer physicians now running communication skills workshops on how to discuss private pay
October 19, 2026 - - Latest News -
'If your doctor prescribes it, it should be covered,' pollster recommends as the key message
October 19, 2026 - - Latest News -
Global headwinds and new contenders set the agenda for Australia's 'Biggest Week in Biotech'
October 19, 2026 - - Latest News -
Mixed PBAC outcomes for multi-cancer immunotherapy listings
October 19, 2026 - -
The committee that rarely fronts is called to answer at Senate Estimates
October 19, 2026 - - Latest News
